The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Non-Viral Drug Delivery Systems Market Through 2030?
The non-viral drug delivery systems market has experienced swift expansion in recent years. This market is projected to increase from $9.84 billion in 2025 to $11.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.4%. The historical growth can be linked to factors such as a reliance on viral delivery methods, limited awareness of non-viral techniques, the emergence of biologics development, the establishment of initial regulatory frameworks for drug delivery, and an early academic research focus on nanoparticles.
The non-viral drug delivery systems market is anticipated to experience significant expansion in the coming years, reaching $19.07 billion by 2030 with a compound annual growth rate (CAGR) of 14.1%. This projected growth during the forecast period is attributable to several factors, including breakthroughs in polymer-based carrier technologies, the proliferation of RNA and DNA therapeutics, increased capital allocation in personalized medicine, the enlargement of contract development and manufacturing organizations (CDMOs), and a surge in partnerships between pharmaceutical companies and academic bodies. Key trends expected within this period involve the increasing embrace of non-viral delivery platforms for targeted therapeutic approaches, a greater deployment of nanoparticles and liposome-based carriers, a concerted effort on minimizing immune reactions while bolstering safety, the development of personalized medicine and precision therapeutics, and the continued expansion of CDMOs alongside academic research partnerships.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
What Key Growth Drivers Are Influencing The Non-Viral Drug Delivery Systems Market?
The growing need for personalized medicines is anticipated to fuel the expansion of the non-viral drug delivery systems market in the coming years. Personalized medicine is a medical approach focused on customizing treatment based on an individual’s genetic makeup, lifestyle, and environment. The demand for personalized medicine is on the rise because it leads to more effective treatments by targeting the specific causes of disease in each patient. Non-viral systems assist personalized medicine by safely delivering drugs or genes to cells, thereby reducing risks and enhancing treatment precision. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, marking an increase from 6 approvals in 2022. Consequently, the increasing demand for personalized medicines is a significant factor propelling the growth of the non-viral drug delivery systems market.
What Are The Major Segment Categories Within The Non-Viral Drug Delivery Systems Market?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
What Trends Are Influencing The Non-Viral Drug Delivery Systems Market?
Leading companies in the non-viral drug delivery system market are concentrating on sophisticated technologies, including pre-optimized ionizable lipid mix systems, to streamline the progression and deployment of RNA-based therapeutics. A pre-optimized ionizable lipid mix system represents a formulation method designed for the effective encapsulation of RNA molecules into lipid nanoparticles, thereby guaranteeing superior stability, safeguarding of the payload, and targeted delivery for applications involving gene-based drugs. For example, in September 2024, Cytiva, a US-based biotechnology company, launched an RNA delivery LNP kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This particular system incorporates a ready-to-use ionizable lipid mix, which allows for rapid screening of various RNA payloads and effective validation of their delivery, especially relevant in the context of developing vaccines for infectious diseases. It seamlessly integrates with automated microfluidic platforms, supports manufacturing at scale using GMP-grade components, and provides detailed protocols alongside proof-of-concept data to guide users from early research discovery to clinical evaluation.
Which Companies Are Influencing The Non-Viral Drug Delivery Systems Market?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
Access The Complete Non-Viral Drug Delivery Systems Market Report:
Which Regional Market Leads The Non-Viral Drug Delivery Systems Market?
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Non-Viral Drug Delivery Systems Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
Browse Through More Reports Similar to the Global Non-Viral Drug Delivery Systems Market 2026, By The Business Research Company
Advanced Drug Delivery Systems Market Report 2026
Electronic Drug Delivery Systems Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model